• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: DAKO NORTH AMERICA, INC. GENPOINT TYRAMIDE SIGNAL AMPLIFICATION SYSTEM FOR BIOTINYLATED PROBES; GENPOINT CATALYZED SIGNAL AMPLIFICATION SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

DAKO NORTH AMERICA, INC. GENPOINT TYRAMIDE SIGNAL AMPLIFICATION SYSTEM FOR BIOTINYLATED PROBES; GENPOINT CATALYZED SIGNAL AMPLIFICATION SYSTEM Back to Search Results
Catalog Number K0620
Device Problem Material Integrity Problem (2978)
Patient Problem No Information (3190)
Event Date 10/20/2015
Event Type  No Answer Provided  
Event Description
Complaint received from a customer in (b)(6) regarding unexpected staining background with use genpoint catalyzed signal amplication system for in situ hybridization.An investigation of the complaint is ongoing.
 
Manufacturer Narrative
Final follow-up information: problem: the complaint reports increased nonspecific granular staining using the genpoint detection system with the genpoint hpv biotinylated probe for cervical cancer screening.The laboratory claimed that the nonspecific staining was severe enough to interfere with the pathologists' interpretation and potentially lead to a (b)(6) result and a misdiagnosis of the patient.No patient harm was reported despite several inquiries by agilent.The laboratory stated that they were unable to improve the test and therefore sent the specimen to another lab.This second lab was able to complete testing.In the absence of any other information about the patient and because the lab was able to complete the test eventually, agilent has concluded that no clinically significant indirect patient harm occurred at that time.Suggested root cause: root cause analysis was inconclusive.Post-retainers from the same genpoint detection system lot were tested in-house on both internal tissue controls and unstained slides from the customer; all stained within specifications.The customer did not return the affected kit.Analysis of the returned stained slides from the customer (negative control with positive stained patient sample) showed that background on the patient sample was slightly higher than seen on samples stained in-house, but their negative control was interpreted to be negative.Because the in-house testing was within specifications, and this complaint is the only complaint related to this lot with a total of 208 kits, it was concluded that the cause was not the kit, but might be due to a laboratory related issue.However, this was not determined for certain.Conclusions: since the root cause analysis suggests this issue may be laboratory related rather than kit related, and this appears to be a unique complaint to this customer, the chance of reoccurrence is low.Should this situation reoccur, a (b)(6) test leading to a (b)(6) diagnosis of (b)(6) and/or high grade cin/squamous cell carcinoma would be unlikely and should be easily detectable as the pattern of nonspecific granular staining is seen throughout the slide and not just within nuclei as is seen with the integrated pattern of (b)(6).A reoccurrence of this situation could cause a delay in test reporting; however, it should not be clinically significant, as other more specific hpv tests are available to detect genotype high risk virus if the assay was being used for this purpose.If ish was desired to allow correlation of morphology with the stain to help differentiate cervical intra-epithelial neoplasia i (cin1) from cinii/iii or squamous cell carcinoma, the delay would still be clinically insignificant, as additional kits from agilent could be shipped within 24-48 hours.Therefore, should this issue recur, it is considered improbable to lead to serious patient harm based on the information given above.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GENPOINT TYRAMIDE SIGNAL AMPLIFICATION SYSTEM FOR BIOTINYLATED PROBES
Type of Device
GENPOINT CATALYZED SIGNAL AMPLIFICATION SYSTEM
Manufacturer (Section D)
DAKO NORTH AMERICA, INC.
6392 via real
carpinteria CA 93013
Manufacturer (Section G)
DAKO NORTH AMERICA, INC.
6392 via real
carpinteria, CA 93013
Manufacturer Contact
mani siravanta
6392 via real
carpinteria, CA 93013
8055665462
MDR Report Key5221852
MDR Text Key31409920
Report Number2022180-2015-00003
Device Sequence Number1
Product Code PPM
Combination Product (y/n)N
Reporter Country CodeSP
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 04/06/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date11/30/2015
Device Catalogue NumberK0620
Device Lot Number10092736
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 10/20/2015
Initial Date FDA Received11/13/2015
Supplement Dates Manufacturer ReceivedNot provided
Supplement Dates FDA Received04/06/2017
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured01/14/2015
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Unknown
Patient Sequence Number1
-
-